Investigational drug · Phase 3
Tiespectus
Also called: EYE201, MK-8748
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
5
Any phase or sponsor naming "Tiespectus"
First trial start
2024
Nov 12, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tiespectus", any sponsor or status.
Conditions studied
As listed on its trial records.
- Macular Degeneration
- Age-Related Macular Degeneration
- Choroidal Neovascularization
- Wet Macular Degeneration
- Diabetic Retinopathy
- Macular Edema
- Diabetic Macular Edema (DME)
- Neovascular Age-related Macular Degeneration (NVAMD)
- BRVO - Branch Retinal Vein Occlusion
Approved drugs for the same conditions: Wet macular degeneration · Diabetic macular edema · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "Tiespectus" as an intervention, largest first.
- A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07705607 · 1,104 participants (planned) · Start Sep 25, 2026 · Primary completion Nov 30, 2028
Drug: MK-8748; Aflibercept · For: Diabetic Retinopathy; Macular Edema
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 31 sites in all
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)Pivotal-lookingRecruiting
EyeBiotech Ltd.Industry
NCT07496567 · 960 participants (planned) · Start Apr 15, 2026 · Primary completion Jul 31, 2028
Drug: Tiespectus; Aflibercept · For: Macular Degeneration; Age-Related Macular Degeneration; Choroidal Neovascularization and 1 more
Sites: Gilbert, Arizona; Phoenix, Arizona; Encino, California · 121 sites in all
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)Pivotal-lookingRecruiting
EyeBiotech Ltd.Industry
NCT07440225 · 960 participants (planned) · Start Mar 27, 2026 · Primary completion Jun 30, 2028
Drug: Tiespectus; Aflibercept · For: Macular Degeneration; Age-Related Macular Degeneration; Choroidal Neovascularization and 1 more
Sites: Scottsdale, Arizona; Fayetteville, Arkansas; Springdale, Arkansas · 148 sites in all
- A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07705555 · 960 participants (planned) · Start Aug 27, 2026 · Primary completion Oct 31, 2028
Drug: MK-8748; Aflibercept · For: Diabetic Retinopathy; Macular Edema
Sites: Gilbert, Arizona; Glendale, California; Sacramento, California · 45 sites in all
EyeBiotech Ltd.Industry
NCT06664502 · 38 participants · Start Nov 12, 2024 · Primary completion Mar 25, 2026
Drug: EYE201 · For: Diabetic Macular Edema (DME); Neovascular Age-related Macular Degeneration (NVAMD); BRVO - Branch Retinal Vein Occlusion
Sites: Scottsdale, Arizona; Modesto, California; Mountain View, California · 27 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Macular Degeneration
- JNJ-81201887AAVCAGsCD59Phase 32 trials
Johnson & Johnson (Janssen) · Geographic Atrophy, Macular Degeneration
- AVD-104Phase 21 trial
Aviceda Therapeutics, Inc. · Geographic Atrophy of the Macula, Macular Degeneration
- SYL1801Phase 21 trial
Sylentis, S.A. · Wet Macular Degeneration, Neovascular Age-related Macular Degeneration, Macular Degeneration
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.